標(biāo)題: Titlebook: Cell Death Signaling in Cancer Biology and Treatment; Daniel E. Johnson Book 2013 Springer Science+Business Media New York 2013 Cancer.Can [打印本頁] 作者: Fillmore 時間: 2025-3-21 20:05
書目名稱Cell Death Signaling in Cancer Biology and Treatment影響因子(影響力)
書目名稱Cell Death Signaling in Cancer Biology and Treatment影響因子(影響力)學(xué)科排名
書目名稱Cell Death Signaling in Cancer Biology and Treatment網(wǎng)絡(luò)公開度
書目名稱Cell Death Signaling in Cancer Biology and Treatment網(wǎng)絡(luò)公開度學(xué)科排名
書目名稱Cell Death Signaling in Cancer Biology and Treatment被引頻次
書目名稱Cell Death Signaling in Cancer Biology and Treatment被引頻次學(xué)科排名
書目名稱Cell Death Signaling in Cancer Biology and Treatment年度引用
書目名稱Cell Death Signaling in Cancer Biology and Treatment年度引用學(xué)科排名
書目名稱Cell Death Signaling in Cancer Biology and Treatment讀者反饋
書目名稱Cell Death Signaling in Cancer Biology and Treatment讀者反饋學(xué)科排名
作者: 過于平凡 時間: 2025-3-21 20:35 作者: Gnrh670 時間: 2025-3-22 01:27 作者: conspicuous 時間: 2025-3-22 07:01
The Role of Autophagy in Drug Resistance and Potential for Therapeutic Targeting,ation, signaling aberrancies, ER stress, DNA damage, systemic cancer therapies, and radiotherapies. There is growing evidence that it may potentiate cancer survival. A number of clinical trials have been launched using autophagy inhibition in combination with standard cancer therapeutics. The inform作者: 鍵琴 時間: 2025-3-22 08:51 作者: 沙漠 時間: 2025-3-22 16:44 作者: 沙漠 時間: 2025-3-22 17:53 作者: 嘮叨 時間: 2025-3-22 23:34 作者: 縮影 時間: 2025-3-23 04:11
Leading Small Molecule Inhibitors of Anti-Apoptotic Bcl-2 Family Members,velopment of resistance to chemo-, radio-, and immunotherapies. Considerable effort is being invested in academic and pharmaceutical settings to identify and design effective small molecule inhibitors of the anti-apoptotic Bcl-2 family members. This chapter will focus on recent advances in the devel作者: RODE 時間: 2025-3-23 07:44 作者: 顛簸下上 時間: 2025-3-23 10:20
Harnessing Death Receptor Signaling for Cancer Treatment,ne side and cell proliferation on the other side toward survival promotes tumor formation. The death receptor (extrinsic) pathway represents one of the major apoptosis signaling cascades, which links exogenous stimuli via transmembrane surface receptors to the intracellular signaling machinery that 作者: LAIR 時間: 2025-3-23 17:01 作者: 最高峰 時間: 2025-3-23 19:55
New Agents and Approaches for Targeting the RAS/RAF/MEK/ERK and PI3K/AKT/mTOR Cell Survival Pathwayutations in intrinsic pathway components. Upstream mutations in one signaling pathway or even in downstream components of the same pathway can alter the sensitivity of the cells to certain small molecule inhibitors. These pathways have profound effects on proliferative, apoptotic, and differentiatio作者: 燈絲 時間: 2025-3-24 00:04 作者: deface 時間: 2025-3-24 03:09
2625-2902 clinical approaches.Features development and application of A key goal in the treatment of cancer is to achieve selective and efficient killing of tumor cells. The aim of .Cell Death Signaling in Cancer Biology and Treatment. is to describe state-of-the-art approaches and future opportunities for ac作者: Endearing 時間: 2025-3-24 09:56 作者: 舊石器時代 時間: 2025-3-24 12:48 作者: 任命 時間: 2025-3-24 18:37 作者: botany 時間: 2025-3-24 20:32 作者: 現(xiàn)存 時間: 2025-3-24 23:34 作者: sclera 時間: 2025-3-25 06:25 作者: abnegate 時間: 2025-3-25 10:16 作者: PLAYS 時間: 2025-3-25 11:57 作者: Indurate 時間: 2025-3-25 17:05
Harnessing Death Receptor Signaling for Cancer Treatment,gulation of the signaling events and their perturbation in human cancers may lead to the identification of new molecular targets that can be exploited for therapeutic purposes. This strategy is expected to open new perspectives to target the death receptor pathway for cancer therapy.作者: 細(xì)微差別 時間: 2025-3-25 22:50
New Agents and Approaches for Targeting the RAS/RAF/MEK/ERK and PI3K/AKT/mTOR Cell Survival Pathwaymotherapeutic drug resistance. This chapter will first briefly describe these pathways and then evaluate potential uses of Raf, MEK, PI3K, Akt, and mTOR inhibitors that have been investigated in preclinical and clinical investigations.作者: 有危險 時間: 2025-3-26 02:37
Wax Control and Removal in Oil Wellopment and application of three small molecule inhibitors (ABT-737, ABT-263, GX15-070), with a particular emphasis on progress that has been made in the evaluation of these compounds in preclinical in vivo models and clinical trials.作者: Venules 時間: 2025-3-26 05:24
Ventilation in Office Buildingss for selective growth inhibition or death by targeting non-redundant pathways in cancer cells. These “metabolic dependencies” are not likely to be associated with classically defined oncogenes or computationally derived drivers and thus may require novel strategies for discovery.作者: DEI 時間: 2025-3-26 09:05
https://doi.org/10.1007/978-981-13-2925-8olipids, are believed to play anti-apoptotic roles and offer drug resistance to currently used chemotherapeutic drugs. These emerging biologic roles of sphingolipids and its potential usefulness in treating cancer in the form of anticancer therapeutics are discussed in this chapter.作者: right-atrium 時間: 2025-3-26 15:28 作者: myalgia 時間: 2025-3-26 17:08
Sphingolipid Metabolism and Signaling as a Target for Cancer Treatment,olipids, are believed to play anti-apoptotic roles and offer drug resistance to currently used chemotherapeutic drugs. These emerging biologic roles of sphingolipids and its potential usefulness in treating cancer in the form of anticancer therapeutics are discussed in this chapter.作者: mediocrity 時間: 2025-3-26 21:27
Book 2013ic modifications, DNA repair pathways, and protein chaperones, as a means of provoking tumor cell death. Finally, the development and application of novel agents and approaches for targeting specific components of cell death signaling pathways and machinery will be reviewed.作者: 迷住 時間: 2025-3-27 04:25
Leading Small Molecule Inhibitors of Anti-Apoptotic Bcl-2 Family Members,opment and application of three small molecule inhibitors (ABT-737, ABT-263, GX15-070), with a particular emphasis on progress that has been made in the evaluation of these compounds in preclinical in vivo models and clinical trials.作者: 箴言 時間: 2025-3-27 05:44
Book 2013 and Treatment. is to describe state-of-the-art approaches and future opportunities for achieving this goal by targeting mechanisms and pathways that regulate cancer cell death. In this book, molecular defects in cell death signaling that characterize cancer cells, including dysregulation of cell de作者: abreast 時間: 2025-3-27 12:28
2625-2902 or cell death. Finally, the development and application of novel agents and approaches for targeting specific components of cell death signaling pathways and machinery will be reviewed.978-1-4939-0107-4978-1-4614-5847-0Series ISSN 2625-2902 Series E-ISSN 2625-2899 作者: 惡意 時間: 2025-3-27 13:53 作者: N斯巴達(dá)人 時間: 2025-3-27 18:55
Assessing IEQ Performance in BuildingsThis has become highly relevant as it is suggested that most cancer cells are likely to be defective in some aspect of DNA repair. Herein, we describe the molecular pathways that participate in the repair of DNA damage induced by radiation- and chemotherapeutics and discuss strategies that are being作者: 催眠 時間: 2025-3-28 01:00
Acids and Additives Used in Acidizingable target for cancer treatment. This idea has been validated from benchtop to bedside. In 2003, the first proteasome inhibitor anticancer drug, bortezomib, was approved in the United States for the treatment of multiple myeloma and mantle cell lymphoma. While bortezomib achieved great success in c作者: 挑剔小責(zé) 時間: 2025-3-28 02:23
Arrivals, Departures and Returnsle environment for the generation of anti-tumor immunity. Activation of immune-mediated tumor cell death by chemotherapy opens the door to the possibility of novel treatment strategies combining standard chemotherapy with immunotherapy agents aimed at enhancing such responses. Preclinical studies an作者: 現(xiàn)代 時間: 2025-3-28 07:08 作者: 蔑視 時間: 2025-3-28 11:40 作者: 征兵 時間: 2025-3-28 15:34 作者: 滋養(yǎng) 時間: 2025-3-28 21:36 作者: 厭食癥 時間: 2025-3-29 01:16 作者: FLIRT 時間: 2025-3-29 06:39 作者: CHAFE 時間: 2025-3-29 10:59
Cell Death in Biology and Diseaseshttp://image.papertrans.cn/c/image/222801.jpg作者: Provenance 時間: 2025-3-29 12:51 作者: coalition 時間: 2025-3-29 16:55 作者: exigent 時間: 2025-3-29 22:47 作者: 無彈性 時間: 2025-3-30 00:37 作者: affinity 時間: 2025-3-30 07:08 作者: 平淡而無味 時間: 2025-3-30 08:22 作者: 柳樹；枯黃 時間: 2025-3-30 14:02
MicroRNAs in Cell Death and Cancer,s are differentially expressed in many solid tumors and often create a unique signature for each tumor type. This chapter explains the function of miRNAs in cancer based on their potential target genes.作者: 跳脫衣舞的人 時間: 2025-3-30 16:54
The Concept of Office and Office Spacesis of cell numbers. Apoptosis also plays a key role in immune-mediated elimination of infected or transformed target cells. In addition, apoptosis drives cellular suicide following damage to DNA or other cell components, including damage resulting from treatment with chemotherapy or radiation. In v作者: 小鹿 時間: 2025-3-30 22:48
Ventilation in Office Buildingsistance to apoptosis. A recent update included deregulated cellular energetics as an emerging hallmark. However, debate about tumor cell metabolism occupied center stage in the pre-oncogene era. Over the last 15?years, direct links of oncogenes and tumor suppressor genes to cell metabolism have brou作者: 溝通 時間: 2025-3-31 02:41
Fundamentals of Office Ergonomicsn. Experimental evidence indicates that these same pathways contribute to de novo drug resistance. Identification of the mechanisms underlying the recruitment of accessory cells and survival signals provided by normal cells has provided a novel area for drug discovery for increasing the efficacy of 作者: Crohns-disease 時間: 2025-3-31 07:43
The Concept of Office and Office Spaceation, signaling aberrancies, ER stress, DNA damage, systemic cancer therapies, and radiotherapies. There is growing evidence that it may potentiate cancer survival. A number of clinical trials have been launched using autophagy inhibition in combination with standard cancer therapeutics. The inform作者: remission 時間: 2025-3-31 09:37
Ergonomics of Computer Workstations are differentially expressed in many solid tumors and often create a unique signature for each tumor type. This chapter explains the function of miRNAs in cancer based on their potential target genes.
